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Amyotrophic lateral sclerosis (ALS) presents moto-
neuron (MN)-selective protein inclusions and axonal
degeneration but the underlying mechanisms of
such are unknown. Using induced pluripotent cells
(iPSCs) from patients with mutation in the Cu/Zn su-
peroxidedismutase (SOD1) gene,weshow that spinal
MNs, but rarely non-MNs, exhibited neurofilament
(NF) aggregation followed by neurite degeneration
when glia were not present. These changes were
associated with decreased stability of NF-L mRNA
and binding of its 30 UTR by mutant SOD1 and thus
altered protein proportion of NF subunits. Such MN-
selective changes were mimicked by expression of a
single copy of the mutant SOD1 in human embryonic
stem cells and were prevented by genetic correction
of the SOD1mutation in patient’s iPSCs. Importantly,
conditional expression of NF-L in the SOD1 iPSC-
derived MNs corrected the NF subunit proportion,
mitigating NF aggregation and neurite degeneration.
Thus, NF misregulation underlies mutant SOD1-
mediated NF aggregation and axonal degeneration
in ALS MNs.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common motor
neuron (MN) disease with no effective treatment (Robberecht
and Philips, 2013). While mostly sporadic, a small population
of patients is associated with genetic mutations, among which
20% are caused by mutations in the Cu/Zn superoxide dismut-
ase (SOD1) gene (Rosen et al., 1993; Deng et al., 1993). The car-
dinal pathology of ALS is MN-selective accumulation of proteins,
especially neurofilament (NF), and axonal degeneration (Carpen-
ter, 1968; Hirano et al., 1984). Transgenic expression of disease-796 Cell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc.linked SOD1 in model organisms results in a similar pathological
outcome. In these animals, protein inclusions are primarily SOD1
and ubiquitin besides NF (Tu et al., 1996; Bruijn et al., 1998;
Wong et al., 1995; Gurney et al., 1994). Protein aggregates
may disrupt axonal transportation, resulting in retraction of
axonal terminals and denervation of muscles before the loss of
cell bodies (Bruijn et al., 1998). Furthermore, SOD1 aggregates
are often present in the mitochondrial intermembrane space in
these animals, which is thought to cause mitochondrial swelling
and vacuole formation (Gurney et al., 1994; Wong et al., 1995).
As these findings occur early in transgenic animals, mitochon-
drial dysfunction is regarded as an early event in ALS patho-
genesis. In addition, mutant SOD1-expressing glial cells also
contribute to ALS pathogenesis, mostly in disease progression
rather than initiation (Clement et al., 2003). Thus, multiple events
can contribute to ALS pathogenesis. However, it remains un-
known how these events interact with each other to initiate the
cascade of axonal degeneration and why MNs are selectively
affected.
Transgenic animals of ALS have been instrumental to our un-
derstanding of ALS pathogenesis. Nevertheless, genetic and
anatomical variations do exist between human and animals. In
particular, mutant SOD1 transgenic mice often require a 20- to
40-fold overexpression of mRNA or a several-fold overexpres-
sion of protein to produce a phenotype (Julien and Kriz, 2006),
as opposed to a single copy in familial ALS patients. This overex-
pression could skew the sequence of events leading to ALS
pathogenesis despite similar outcomes. Accordingly, therapeu-
tics developed with these model animals do not readily translate
into clinics, as indicated by the fact that none of the drugs that
tested positively in ALS animals have proven successful in clin-
ical trials (Musaro`, 2013).
A model with naturally occurring pathology under the human
genetic background could complement existing models and
potentially facilitate clinical translation. This is made possible
with induced pluripotent stem cells (iPSCs) from patients (Han
et al., 2011). Modeling diseases with iPSCs faces a number
of technical challenges, including variation among individuals,
heterogeneity of differentiated (target) cells, and immaturity of
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notypes seem to appear in ‘‘young’’ neural cells that are differen-
tiated from patient iPSCs, including ALS, Alzheimer’s disease,
and Parkinson’s disease (Israel et al., 2012; Jiang et al., 2012;
Serio et al., 2013). We have developed methods to efficiently
differentiate human stem cells to a synchronized population of
mature MNs based on previous reports (Li et al., 2008), allowing
investigation of differential pathological changes in MNs versus
non-MNs. Furthermore, gene-editing technology, such as
transcription activator-like effector nucleases (TALEN), allows
genetic correction of mutations or knockin of a disease-causing
mutation at a particular locus within the human genome (Hocke-
meyer et al., 2011; Soldner et al., 2011), thus providing
‘‘isogenic’’ controls and minimizing variation (Qian et al., 2014).
By using these strategies, we found that NF aggregation
followed by neurite swelling appeared early in spinal MNs, but
rarely in non-MNs, that were derived from iPSCs with SOD1
(D90A and A4V) mutations at a timewhen glial cells were not pre-
sent. These changes were associated with binding of mutant
SOD1 in the 30 UTR of NF-L mRNA, decreased stability of NF-L
mRNA, and altered proportion of NF subunits. Such MN-selec-
tive NF changes were mimicked by expression of a single copy
of mutant SOD1 (D90A) in human embryonic stem cells (hESCs)
and prevented by genetic correction of the SOD1 mutation
in patient iPSCs. Importantly, conditional expression of NF-L in
mutant SOD1 iPSCs restored the proportion of NF subunits,
prevented NF aggregation, and mitigated neurite swelling, high-
lighting NF misregulation as a critical component of MN degen-
eration in ALS.
RESULTS
ALS iPSCs and Genetically Corrected ALS iPSCs
Differentiate to MNs Efficiently
We obtained an iPSC line with an A4V SOD1mutation from Cor-
iell that was established by retrovirus. We generated iPSC lines
from fibroblasts that carry D90ASOD1mutation (Coriell) by using
the nonintegrating Sendai virus (Ban et al., 2011). A4V is themost
common SOD1mutation in the US and D90A is most common in
Europe (Giannini et al., 2010; Saeed et al., 2009). iPSCs reprog-
rammed with Sendai virus were integration free as confirmed by
qPCR analysis for viral sequences (Figure S1A available online).
All iPSCs became stable cell lines; exhibited typical morphology;
expressed pluripotency markers including NANOG, OCT4,
SSEA-4, and SOX2; generated teratomas in vivo; and retained
karyotype stability (Figures 1A, 1B, and S1B–S1D). The SOD1
D90A mutation was maintained as confirmed by sequencing
exon 4 of SOD1 (Figure 1C). Two clones from each of the iPSC
lines (except A4V), genetically corrected lines, and transgenic
lines were used (Table S1 available online).
iPSCs from different individuals can be variable (Hu et al.,
2010), whichmakes it difficult tomodel disease processes (Sold-
ner et al., 2011). To establish isogenic controls under the same
genetic background, we corrected the D90A mutation in iPSCs
using TALEN (Figure S1E). PCR analysis of individual single-
cell-derived G418-resistant clones using a primer external to
the 50donor homology region and a primer against the PGK
promoter demonstrated disruption of the genomic locus and
integration of the donor vector with a frequency of about 45%(Figure S1F). Two selected clones, designated as D90D-1 and
D90D-2, showed successful correction of the targeted locus,
as revealed by TaqMan SNP genotyping assays (Figure S1G)
and by sequencing (Figure 1D). The corrected iPSCs displayed
a normal karyotype, uniform expression of pluripotencymarkers,
and generation of teratomas, as well as polymorphisms identical
to those of their parental cells as assayed by short tandem repeat
(STR) analysis (Figure S1H) and genomic integrity (Table S2).
To identify whether SOD1 mutations affect MN generation
in vitro, we used a differentiation protocol modified fromprevious
methods (Figure 1E) (Li et al., 2008). We found that mutant (D90A
and A4V) and genetically corrected (D90D) SOD1, as well as WT
(IMR-90-4) iPSCs efficiently differentiated into OLIG2+ MN pro-
genitors at day 14, MNX1+/ISLET1+ postmitotic MNs at day 21,
and CHAT+ maturing MNs by 21–30 days (Figures 1F, 1G and
S1I), with 94% of the TUJ1+ neurons, or 90% of total differenti-
ated cells, being MNX1+ MNs (Figures 1H and 1I). Two weeks
(day 12) after plating day 21 cells, 85% of MNs were induced
to fire action potentials besides basic neuronal properties (Fig-
ures S1K–S1N). They also formed neuro-muscular junctions
when cocultured with C2C12 myocytes as indicated by bungar-
otoxin (BTX) staining on myotubes (Figure S1J). As a non-MN
control within each line, we also differentiated these iPSCs to
spinal neurons that were void of MNX1+ or CHAT+MNs by block-
ing hedgehog signaling using cyclopamine during neural
patterning (Figures 1E and S1O). The vast majority of these
non-MNs were GABA neurons (Figure S1O). At 4–5 weeks of
iPSC differentiation for either MN or non-MN cultures, no glial
fibrillary acidic protein (GFAP)-expressing astrocytes were
observed (Figures 1F and 1G). Additionally, we used a Notch
signaling inhibitor (compound E) prior to maturation to prevent
generation of new neurons or glia from progenitors, thus creating
highly enriched and synchronized MNs and non-MNs. These re-
sults indicate that SOD1 mutations do not affect MN develop-
ment and treatment with compound E substantially accelerates
neuronal maturation.
Mutant SOD1 Forms Small Aggregates in MNs
To assess the effect of mutant SOD1, we determined the relative
expression level of mutant SOD1 during reprogramming and
neural differentiation. Using qPCR, we found that the ratio be-
tween mutant and WT alleles was about 1 in fibroblasts, iPSCs,
neuroepithelia, MN progenitors, MNs, and non-MNs for the
D90A mutant (Figure 2A), indicating that the mutant SOD1
copy is maintained during reprogramming and neural differenti-
ation. Furthermore, we found that ALS MNs and non-MNs ex-
pressed similar SOD1 mRNA levels, independent of mutational
status, to those of WT and genetically corrected ALS cells (Fig-
ure 2B). Western blotting indicated that SOD1 protein was
approximately 40% lower in day 30 MNs than in non-MNs for
all groups (Figure 2C). Interestingly, mutant MNs expressed an
even lower level of SOD1 than WT and genetically corrected
MNs (Figure 2C). This unexpected pattern of changes was repli-
cated in six sets of biological samples. Thus, total SOD1 protein
does not increase in ALS patient MNs at the stage analyzed.
Expression of multiple copies of disease-causing SOD1 in ani-
mals results in its aggregation (Bruijn et al., 1998). Immunostaining
for SOD1 showed a ubiquitous expression pattern without
discernible aggregates in MNs (Figure S2A). We reasoned thatCell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc. 797
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Figure 1. iPSC Generation, Neural Differentiation, and Mutation Correction
(A) Contrast image of iPSC colonies.
(B) Immunofluorescent image of NANOG expression in D90A SOD1 iPSCs.
(C and D) DNA sequencing showing heterozygous nucleotides (A/C) in D90A (C) and homozygous nucleotide A in corrected (D90D) (D) SOD1 iPSCs.
(E) Schematic protocol for MN and non-MN differentiation. Human PSCs were differentiated to neuroepithelia (NE) in the presence of three small molecular
compounds (3c) for 7 days before being patterned to spinal progenitors for 7 days with morphogens (Pur, purmorphamine; Cyclo, cyclopamine). The progenitors
were expanded in suspension for 1 week and then plated onto laminin substrate for differentiation to postmitotic neurons from day 21.
(F and G) ALS (D90A) and genetically corrected ALS (D90D-1) iPSCs differentiated to OLIG2+ MN progenitors at day 14, MNX1+ postmitotic MNs at day 21, and
CHAT+ maturing MNs at day 28.
(H and I) Quantification of TUJ1+ neuronal population among total Hoechst (HO)-labeled cells (H) and MNX1+ MNs among neurons (I).
Scale bar = 50 mm. Data are represented as mean ± SEM.
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Figure 2. SOD1 Expression and Aggregation in iPSC-Derived Neurons
(A) Allelic imbalance assay showing the ratio of mutant (A) and WT (C) copy of SOD1 transcripts in fibroblasts (FIB), reprogrammed stem cells (iPS), their
differentiated neuroepithelia (NEP), MN progenitors (MNP), MNs, and non-MNs.
(B) RT-qPCR analysis showing SOD1 mRNA expression in MNs and non-MNs.
(C) Representative western blots and relative SOD1 expression levels (to neuron-specific enolase) in MNs and non-MNs.
(D) SOD1 immuno-EM in neurites, cytoplasm, nuclei, and mitochondria of MN and non-MN cultures. Arrows indicate clusters of gold particles. No contrast
staining for ALS non-MNs for better view of fine gold particles. Scale bar = 2 mm. Data are represented as mean ± SEM.
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Figure 3. NF Inclusions in ALS iPSC-Derived Neurons
(A) Immunofluorescent images of NF-H, NF-M, and NF-L in CHAT+ MNs. NF staining in the insets is magnified on the right panel. Arrows indicate NF inclusions in
the cell body; arrowheads indicate NF inclusions in neurites. Scale bar = 50 mm.
(B) EM showing NF arrangement in cell body (left) and neurites (right) of MN cultures. Scale bar = 2 mm.
(C and D) Quantification of NF inclusion-containing cell bodies (C) and neurites (D) in MNs and non-MNs at day 4, 7, and 10 after plating. Data are represented as
mean ± SEM, *p < 0.05. 150–200 neurons and 500 neurites per cell line were counted.
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Neurofilament Misregulation in ALS Pathogenesisaggregatesmay be absent or too small to discern under confocal
microscopy. Immuno-electron microscopy (immuno-EM) re-
vealed an even distribution of fine gold particles in cytoplasm
and neurites of MN cultures from WT and genetically corrected
ALScells. InALSMNcultures, clusters of goldparticles, averaged
64 ± 5 nm in diameter, were present in cytoplasm, neurites, and
nuclei (Figure 2D). In transgenic animals, SOD1 aggregates are
often present on mitochondrial membrane (Gurney et al., 1994;
Wong et al., 1995). Careful examination revealed no association
of SOD1 aggregates with mitochondria (Figure 2D). In ALS non-
MN cultures, there were more gold particles than in MNs, but
they were singular, of 10.73 ± 1.07 nm in diameter (Figure 2D,
noncontrasted image to reveal fine particles). Thus, small SOD1
aggregates are present in the cytoplasm, nuclei, and neurites of
ALS MNs, but not in mitochondria.
ALS MNs Exhibit NF Inclusions
NF inclusion in the perikaryon and proximal axons of spinal
MNs is a hallmark of ALS pathology (Carpenter, 1968; Hirano
et al., 1984). Immunostaining for NF-200(H), NF-145(M), and
NF-68(L) at day 30 revealed distinct, focal accumulation of800 Cell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc.immunoreactive products in cytoplasm and neurites of CHAT+
ALS MNs (Figure 3A). Such NF aggregates were rare in ALS
non-MNs (Figure S3A) or MNs from WT and genetically cor-
rected ALS iPSCs (Figure 3A). Inclusions in the cytoplasm and
proximal neurites were often accompanied by lower immunoflu-
orescent intensity for NF (Figure 3A) and other proteins (CHAT,
see Figure S2A) in distal neurites, giving the appearance of
shorter and fewer neurites. However, the distribution of bIII-
tubulin in ALS MN neurites was not altered (Figure S3B). The
identity of the inclusions was confirmed by immuno-EM,
showing disorganized or swirling NFs near the nucleus or in
the proximal neurite (Figure 3B).
Quantification of NF inclusions (defined as focal accumulation
of immunoreactive products with the intensity being three times
higher than in its surroundings) indicated an increasing number
of ALS MNs and their neurites that contained NF inclusions at
day 25, 28, and 31, or 4, 7, and 10 days after plating day 21 cells
for maturation (Figures 3C and 3D). By day 10, over 60% of the
MN cell bodies or 25% of neurites contained NF inclusions and
the average size of the NF inclusion was 42.4–75.4 mm2 in
cell bodies and 1.75–5.53 mm2 in neurites. WT and genetically
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Figure 4. Degenerative Changes in ALS MN Neurites
(A) Colorimetric measurement of LDH (normalized to gDNA) in culture media from MN and non-MN cultures.
(B and C) Cleaved caspase-3 staining (arrows) and quantification.
(D) Phase contrast images of MNs and non-MNs at day 10. Arrows indicate bead-like swellings in neurites. Inset is magnified in upper right.
(E) Immunofluorescent images of p-NF-H in MNs and non-MNs. Arrowheads indicate bead-like structures in neurites. Inset magnified in upper right.
(F) Quantification of beads on neurites.
(G) ELISA quantification of p-NF-H in media (normalized to gDNA).
*p < 0.01. Scale bar = 50 mm. Data are represented as mean ± SEM.
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inclusions over time but at a significantly lesser degree, reaching
about 20% of cells and 8%of neurites by day 10 (Figures 3C and
3D). Fewer NF inclusions existed in non-MNs as compared to
MNs in ALS cells (Figures 3C and 3D). Thus, NF inclusions are
preferentially present in ALSMNs, andmoreMNs contain aggre-
gates over time.
NF inclusions were often associated with accumulation of
mitochondria (Figure 3B). However, mitochondrial swelling or
vacuole formation was not observed in ALS human MNs (Fig-
ure 3B). Thus, mitochondrial swelling or vacuolization is not
obvious at a time when NF aggregation is present.
ALS MNs Undergo Neurite Degeneration
Since ALSMNs contain NF inclusions, we asked if these neurons
undergo degeneration or cell death. Measurement of lactate
dehydrogenase (LDH), a cytosolic enzyme released during cell
death, showed no obvious difference among ALS, WT, and cor-
rected MNs or non-MNs at day 10 (Figure 4A). Immunostaining
for cleaved caspase-3 showed no significant difference amongthe groups (Figure 4B, C). These results suggest that the aggre-
gate-containing MNs are surviving at this stage.
Interestingly, we observed bead-like swellings along neurites
of ALS MNs under phase contrast microscopy as early as day
7–10 after plating. At day 10, 25% ± 2.4% neurites in ALS
MNs presented bead-like structures whereas only 5% ± 0.4%
of the neurites had such structures in control MNs (Figures 4D
and 4F). Few non-MNs exhibited beading structures (Figures
4D and 4F). Aggregated NF as well as axonal NF is often heavily
phosphorylated (Goldstein et al., 1983; Lee et al., 1986). Plasma
phosphorylated neurafilament-H (p-NF-H) levels closely reflect
disease progression in SOD1 (G93A) mice and are regarded as
an ALS biomarker (Calvo et al., 2012). Indeed, immunostaining
for p-NF-H showed dense staining in the bead structures
of ALS MN neurites, giving a dotted staining appearance as
opposed to an even staining pattern in control MNs or non-
MNs (Figure 4E). Similarly, CHAT staining signal was concen-
trated in bead formations (Figure 4E) and was weak in other
areas of neurites (Figure S2A). ELISA measurement of p-NF-H
in culture media indicated that its concentration in ALS MNsCell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc. 801
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ure 4G). The p-NF-H level in non-MNs across all groups was very
low (Figure 4G). With extended cultures (day 20), we observed
increased numbers of beads along neurites and fragmentation
of neurites (Figure S4A), suggesting neurite degeneration at a
later stage. Indeed, TUNEL staining showed a significantly
increased number of dead cells in the ALS group compared
with WT and D90D groups at day 20 after plating. (Figures S4B
and S4C). These results indicate a sequential change in NF ag-
gregation, neurite swelling, and MN degeneration.
Expression of Mutant SOD1 in hESCs Results in MN-
Selective NF Aggregation and Neurite Degeneration
To further establish the cause-effect relationship between
mutant SOD1 and the above MN pathology, we expressed
the D90A mutant SOD1, WT SOD1 (control), or EGFP (control)
in hESCs (H9 line) in the PPP1R12C (AAVS1) locus by TALEN-
mediated homologous recombination (Figures S5A and S5B).
Western blotting showed a 2.8-fold increase in SOD1 protein
in the mutant SOD1-expressing, but not WT SOD1-expressing,
group as compared to the EGFP group after differentiation
to MNs and non-MNs (Figure 5A). Expression of D90A SOD1
or EGFP did not alter the differentiation of the hESCs to
MNs or non-MNs. We observed, similar to that in ALS cells, pro-
gressively increased numbers of NF inclusions in both cell
bodies and neurites of MNs that were derived from the D90A
SOD1-expressing, but not EGFP-expressing, ESCs over time
(Figures 5B–5D). However, no significant difference in NF inclu-
sions was discerned in non-MNs between the D90A SOD1-
expressing and the EGFP-expressing groups (Figures 5C, 5D,
and S5C).
Analysis of neurite degeneration indicated that 90%±2%neu-
rites presented bead-like structures in D90A SOD1-expressing
MNs compared to only 4% ± 0.3% of MN neurites in the
EGFP-expressing group at day 10 (Figure 5E). Few non-MNs
exhibited beading structures (Figure 5E). The p-NF-H in culture
media was 6-fold higher in the D90A SOD1-expressing MNs
than in the EGFP-expressing MNs and was barely detectable
in non-MNs (Figure 5F). Measurement of LDH in the culture
media showed no significant difference among all groups (Fig-
ure 5G). These results indicate that expression of one copy of
mutant SOD1 (D90A) is sufficient to cause the same disease
phenotypes that are seen in cells with naturally occurring muta-
tions. These findings also suggest that secondary genetic muta-
tions inherent to the D90A iPSCs are not critical for formation of
disease phenotypes.
ALS MNs Exhibit Altered NF Subunit Proportion
The above results suggest that NF aggregation is an early and
key event leading to MN axonal degeneration. NFs are assem-
bled by copolymerization of NF-L, NF-M, and NF-H in a tightly
coordinated manner (Hoffman and Lasek, 1975). Transgenic
disruption of their balance results in NF aggregation and MN
degeneration (Coˆte´ et al., 1993; Xu et al., 1993), resembling
ALS pathology. By RT-qPCR analysis, we found no difference
in the expression of NF-H and NF-M mRNA between ALS and
control (WT and D90D) MNs (Figure 6A). However, NF-L mRNA
was reduced by40%–60% in ALSMNs as compared to control
MNs (Figure 6A). In non-MNs, no obvious expression difference802 Cell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc.between the disease and control groups was observed for any
NF isoform (Figure 6A).
At the protein level, western blot analysis revealed that NF-H,
NF-M, and NF-L were all decreased in ALS MNs, but not in non-
MNs, as compared to control cells (Figure 6B). NF-L was most
prominently downregulated in ALS MNs, representing only
30% of the level of WT MNs (Figure 6B). Because NF-L was
downregulated more than the other two subunits, the proportion
of NF subunits was altered in ALS MNs, but not in non-MNs
(Figure 6C).
A similar pattern of alteration in NF subunit mRNA and protein
was observed in MNs, but not non-MNs, that were derived
from hESCs expressing D90A SOD1, but not EGFP (Figures
S6A–S6C), further supporting that mutant SOD1 alters NF
compositions.
Mutant SOD1 Binds the 30 UTR of NF-L mRNA and
Destabilizes NF-L mRNA
To understand why NF-L mRNA is specifically decreased, we
performed an RNA stability assay. Interestingly, the decay of
NF-L, but not b-actin, mRNA accelerated significantly in ALS
compared to control MNs in the presence of actinomycin D (Fig-
ure 6D).NF-LmRNA is regulated by its 30 UTR (Szaro and Strong,
2010), and multiple proteins, including mutant SOD1 (Ge et al.,
2005), bind and potentially regulate NF-L mRNA. Using an NF-
L 30 UTR RNA probe, we found that SOD1 was indeed present
in both D90A and D90D MNs when blotted with a regular
SOD1 antibody. Strikingly, in the elutes of D90A MNs, but not
non-MNs, SOD1 displayed an extra band that migrated slightly
faster (Figure 6E). This band, but not the common 20 kD band
in the input samples (more protein), was recognized by A5C3
(Figure 6F), an antibody that detects some misfolded SOD1
(Gros-Louis et al., 2010). This result indicates specific binding
of mutant SOD1 to 30 UTR of NF-L mRNA in ALS MNs.
Correction of NF Subunit Proportion Mitigates NF
Aggregation and Neurite Degeneration
Our findings suggest that mutant SOD1 alters the proportion of
NF subunits, leading to NF aggregation and neurite degenera-
tion. To test this hypothesis, we conditionally expressed NF-L
or EGFP (control) in the PPP1R12C locus of D90A iPSCs by
TALEN-mediated homologous recombination (Figure S7A). As
indicated by dose-dependent changes in EGFP intensity (Fig-
ure S7B), the expression level of NF-L was increased in a
dose-dependent manner when DOX was added to the MN cul-
tures at day 21, as shown by western blotting (Figures S7C–
S7F). Remarkably, induction of exogenous NF-L, but not
EGFP, in the ALS MNs not only increased the expression of
NF-L, but also NF-H and NF-M (Figure 7A). At 1 mg/ml DOX,
the ratio of NF-L was close to that in WT or genetically corrected
MNs (Figure 7B). Importantly, NF-L-expressing ALS MNs ex-
hibited fewer NF inclusions in both cytoplasm and neurites at
day 10 after plating when compared to EGFP-expressing ALS
MNs, with approximately 30% and 50% reduction in cytoplasm
and neurites, respectively (Figures 7C and 7D). Similarly, the
proportion of bead-containing MN neurites was 12% in NF-L-
expressing cells compared to 25% in GFP-expressing cells
(Figures 7E–7G). Presence of p-NF-H in culture media from
NF-L-expressing ALS MNs was significantly lower than from
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Figure 5. NF Aggregation and Neurite Degeneration in WT Neurons Expressing D90A SOD1
(A) Western blots and relative expression of SOD1 (to GPDH) in MNs and non-MNs derived from hESCs expressing D90A SOD1, WT SOD1, or EGFP.
(B) Immunofluorescent images of NF-H, NF-M, and NF-L in CHAT+ cells from SOD1- and EGFP-expressing hESCs. NF staining in the insets is magnified on the
right panel. Arrows indicate NF inclusions in the cell body; arrowheads indicate NF inclusions in neurites.
(C and D) Quantification of NF-inclusion-containing cell bodies (C) and neurites (D) at day 4, 7, and 10.
(E) Phase contrast images of MNs and non-MNs from mutant SOD1-and EGFP-expressing hESCs. Arrows indicate bead-like formations in neurites. Inset is
magnified in upper right.
(F and G) p-NF-H (F) and LDH (G) in culture media from MN and non-MN cultures derived from SOD1- or EGFP-expressing hESCs. Data are represented as
mean ± SEM.
*p < 0.05; **p < 0.01. Scale bar = 50 mm.
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Figure 6. Expression, Stability, and Protein Binding of NF Subunits in Neurons
(A) RT-qPCR analysis of NF-H,NF-M, and NF-L relative toGAPDH in MNs (upper panel) and non-MNs (lower panel) from ALS (D90A, A4V), genetically corrected
(D90D-1 and D90D-2), and WT (IMR-90-4) iPSCs.
(B) Western blots and relative (to NSE) expression of NF-H, NF-M, and NF-L in MNs and non-MNs. Representative blots are shown on the right.
(C) The proportion of NF-L among total NF protein in MNs (upper panel) and non-MNs (lower panel). Data are represented as mean ± SEM.
*p < 0.05 between ALS (D90A, A4V) and genetically corrected ALS (D90D) or WT (IMR-90-4) cells.
(D) Relative levels of NF-L and b-actin mRNA in ALS (D90A) and corrected (D90D) MNs in the presence of actinomycin D measured by RT-qPCR. Data are
represented as mean ± SEM (p < 0.05 between D90A and D90D).
(E) Western blotting for mutant SOD1 in MN and non-MN samples pulled down by the 30 UTR NF-L mRNA probe.
(F) Input samples were blotted for A5C3 antibody.
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Neurofilament Misregulation in ALS PathogenesisGFP-expressing ALS MNs (Figure 7H). Together, these results
indicate that induction of NF-L in ALS MNs largely restores
NF subunit proportion, reduces NF aggregation, and mitigates
neurite degeneration.
DISCUSSION
Modeling Early Pathological Events Using Human Stem
Cells
Modeling diseases with human stem cells faces challenges
with large variation among individuals, heterogeneity of target
cells, and immaturity of target cells for phenotypic presentation.
To overcome variation, we not only used iPSCs from ALS pa-
tients with different mutations (D90A and A4V SOD1), but also
employed TALEN-based homologous recombination to correct
the D90A SOD1 mutation as well as to express the same muta-
tion in hESCs. That enables direct comparison between the mu-
tants and controls under the same human genetic background
and establishes the cause-effect relationships between disease
SOD1 and MN defects. To overcome heterogeneity and imma-
turity of disease target cells (e.g., MNs), we have established
a system that allows generation of MNs at as high as 90%
MNX1-expressing and CHAT-expressing MNs among the differ-
entiated progenies by a simple modification of the initial neuro-
epithelial differentiation step using three small molecules (Xi
et al., 2012; Chambers et al., 2009), especially the GSK3b inhib-804 Cell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc.itor, CHIR99021, to synchronize the primitive neuroepithelia for
subsequent patterning. Treatment with a Notch signaling inhib-
itor further synchronizes the production of more mature MNs
and non-MNs by preventing the generation of waves of later-
born neurons or glial cells. It also accelerates neuronal matura-
tion, as indicated by action potential firing in 85% of neurons
as early as day 12. These strategies enable identification of sub-
tle and otherwise indiscernible biochemical changes in target
cells and ensure confidence in results obtained from the
in vitro model.
Such a system reveals that MNs express a substantially larger
amount of NF and lower levels of SOD1 than non-MNs do. The
even lower level of total SOD1 protein in mutant human MNs
contrasts the substantially increased SOD1 level in most trans-
genic animals (Julien and Kriz, 2006). One may argue that
the lower level of SOD1 proteins is due to loss of insoluble
SOD1 during sample preparation. However, we rarely observed
SOD1 aggregates unless using immuno-EM. In particular, we
used a solvent that has been shown to dissolve most proteins,
including aggregated SOD1 (Wang et al., 2003). When mild lysis
buffer is used, the mutant and WT SOD1 are resolved and they
exhibit a roughly 1:1 ratio (Figured 6E and 6F). Hence, the SOD1
level is at least not increased in the ALS human MNs, similar to
the unaltered SOD1 level in ALS patient spinal cord homogenate
(Jonsson et al., 2004). These findings highlight the significance
of enriched disease target cells for uncovering fundamental
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Figure 7. Effects of NF-L Expression on NF Aggregation and Neurite Degeneration in ALS MNs
(A) Western blots and relative (to NSE) expression of NF-H, NF-M, and NF-L in MNs from GFP-, NF-L-expressing ALS (D90A) iPSCs as well as genetically
corrected (D90D-1 and D90D-2) ALS iPSCs.
(B) The proportion of NF-L among total NF protein in the presence of 1 mg/ml of DOX.
(C and D) Quantification of NF-inclusion-containing cell bodies (C) and neurites (D) in MNs.
(E) Phase contrast images of MNs at day 10. Arrows indicate bead-like swellings in neurites. Inset is magnified in upper right.
(F) Immunofluorescent images of p-NF-H in MNs. Arrowheads indicate bead-like structures in neurites.
(G) Quantification of bead-like formations.
(H) ELISA quantification of p-NF-H in media from MN cultures.
Scale bar = 50 mm. Data are represented as mean ± SEM, *p < 0.05.
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type-specific vulnerability and phenotypic presentation.
NF Aggregation Is an Early Event in ALS Pathogenesis
Crucial to revealing disease pathogenesis is identification of
early molecular and cellular events. In SOD1 transgenic mice, in-
clusion of SOD1 and ubiquitin and in some cases mitochondrial
swelling is often seen before axonal degeneration and disease
onset (Bruijn et al., 1998; Gurney et al., 1994). In human ALS
MNs, however, SOD1 aggregation and mitochondrial swelling
are not obvious. This may be due to the relatively low levels of
SOD1 in human ALS neurons. Indeed, transgenic mice that ex-
press lower levels of mutant SOD1 do not show SOD1 aggrega-
tion (Gurney et al., 1994). Interestingly, the low level of mutant
SOD1, either present in the naturally occurring disease cells or
expressed in WT cells, is sufficient to result in NF aggregation
as early as 4 days after plating. The identity of NF aggregates
in cultured human MNs is verified by EM and they resemble
those in ALS patient spinal cord (Carpenter, 1968; Hirano
et al., 1984). While NF pathology observed in ALS patients is
generally from the end stage of the disease, our finding with
cultured ‘‘young’’ neurons strongly suggests that NF aggregation
is an early event in ALS pathogenesis.
Prominent NF aggregation is followed by bead-like swelling in
MN neurites. This focal bead-like swelling is morphologically
reminiscent of swollen axons in ALS patients and transgenic
mice. The degenerating nature of the bead-like swelling is also
characterized by focal staining of CHAT and phosphorylated
NF as well as leakage of p-NF-H into culture media. Interestingly,
no obvious increase in cell death is detected either by measure-
ment of LDH in the media or caspase staining in MNs at this
stage, suggesting that the neurites undergo degeneration before
MN death in our culture system. The phenomenon of neurite
degeneration independent of death of the parental cell body
has been observed in ALS transgenic animals (Bruijn et al.,
1998; Tu et al., 1996; Fischer et al., 2004). Nevertheless, with
extended culture these MNs ultimately degenerate. The striking
sequential appearance of NF aggregation and neurite degenera-
tion is reproducible not only in MNs with different SOD1 muta-
tions but also in those derived from mutant SOD1-expressing
hESCs. This phenomenon highlights the recapitulation of key
ALS pathology in vitro under a defined condition over a substan-
tially shortened period.
NF Misregulation Underlies NF Aggregation and Neurite
Degeneration in ALS MNs
NF aggregation has been observed in ALS patients and trans-
genic animals (Carpenter, 1968; Hirano et al., 1984; Bruijn
et al., 1998; Tu et al., 1996), and transgenic alteration of NFs
in neurons, especially overexpression, can cause ALS-like pa-
thology (Coˆte´ et al., 1993; Xu et al., 1993). This gives a percep-
tion that increased amount of NF underlies NF aggregation, and
it has support from a study in which deletion of NF in SOD1 mice
mitigates disease phenotypes (Williamson et al., 1998). That
would contrast our finding that NF is decreased in ALS MNs.
It should be noted, however, that in ALS patients there is a
60% reduction in NF-L mRNAs in MNs using in situ hybridiza-
tion (Bergeron et al., 1994), consistent with our results in vitro.
Our observation that conditional expression of NF-L prevents806 Cell Stem Cell 14, 796–809, June 5, 2014 ª2014 Elsevier Inc.NF aggregation also conforms to that in transgenic animals in
which mating of SOD1 mice with NF-L- or NF-H-overexpressing
mice mitigates symptoms and extends life span (Kong and Xu,
2000; Couillard-Despre´s et al., 1998). Furthermore, disease
phenotypes in NF-H-overexpressing mice are mitigated by co-
overexpression of NF-L (Meier et al., 1999). These in vitro and
in vivo studies from both human and transgenic animals sug-
gest that it is not a simple increase or decrease of NF that re-
sults in NF aggregation, but rather it is the altered stoichiometry
of NF subunits triggered by increase or decrease of one of the
subunits that elicits disorganization of NF. Indeed, when we
conditionally expressed NF-L to the level by which the proper
proportion of NF subunits is restored, NF aggregation and
neurite degeneration are mitigated in ALS human MNs even in
the presence of SOD1 mutations. We therefore propose that
alteration of NF subunit proportion leads to NF aggregation in
ALS MNs.
By gain-of-function (expression of mutant SOD1 in hESCs)
and loss-of-function (genetic correction of D90A SOD1 muta-
tion) analysis, we have now established unequivocally that
mutant SOD1 leads to misregulation of NF subunits. This in
turn results in NF aggregation and neurite degeneration as evi-
denced by our rescue experiment to correct NF subunit pro-
portion. An important question is how mutant SOD1 alters NF
expression. Expression of NF is modulated at multiple levels,
including mRNA transcription, localization, stability, and transla-
tion (Szaro and Strong, 2010). We found that NF-L mRNA ex-
hibits reduced stability in ALS MNs. It is known that mutant
SOD1 binds the 30 UTR of NF-L mRNA and destabilizes NF-L
mRNA, at least based on analysis in an immortalized cell line
(Ge et al., 2005). Strikingly, we found that mutant SOD1 specif-
ically binds the 30 UTR of NF-L mRNA in ALS, but not control,
MNs. We thus propose that mutant SOD1 binds 30 UTR of
NF-L mRNA and destabilizes NF-L mRNA, leading to altered
stoichiometry of NF subunits and subsequent NF aggregation
in MNs.
Selective MN Pathology in a Cell-Autonomous Manner
As presented by ALS patients and transgenic animals, the cardi-
nal ALS pathology (NF inclusions and axonal degeneration) is
present in MNs but rarely in non-MNs that are derived from
ALS patient iPSCs. The mechanisms underlying MN-selective
vulnerability in ALS, a general and central question to neurode-
generative disorders, remains unknown. Our ability to generate
enriched populations of MNs and non-MNs begins to reveal
interesting aspects of human MN properties. The lower level
of SOD1 in MNs, seemingly counterintuitive given the need to
counteract oxidative metabolites produced in highly metabolic
large cells like MNs, may render MNs more susceptible to stress
than non-MNs even thoughmutant SOD1 causes ALS via a toxic
gain of functionmechanism (Bruijn et al., 1998). The substantially
higher NF content in MNs demands tight regulation and makes
MNs prone to misregulation and aggregation (Julien and Kriz,
2006). Our finding that NF-L mRNA in MNs, but not non-MNs,
is altered in the presence of mutant SOD1 indicates a cell-
type-specific regulation of NF expression. Even though mutant
SOD1 is present in both MNs and non-MNs, the interaction
between mutant SOD1 and NF-L mRNA in MNs, but not
non-MNs, likely also contributes to MN-selective changes. The
Cell Stem Cell
Neurofilament Misregulation in ALS Pathogenesisenriched neuronal subtypes from ALS patients allow further
interrogation of selective MN pathogenesis in ALS.
AlthoughMNs are selectively affected at an early stage of ALS,
its pathogenesis involves non-MN cells, especially glia. Chimeric
transgenic studies have shown unequivocally that mutant SOD-
expressing astrocytes exacerbate progression of the disease
processwhereasWT astrocytesmitigate the pathology (Clement
et al., 2003). In our culture system, GFAP-expressing astrocytes
are absent within 5 weeks of culture, similar to previous reports
(Serio et al., 2013; Krencik et al., 2011). The fact that MN pathol-
ogy is observed in the absence of glial cells indicates that ALS
pathology can occur in a cell-autonomous manner. This conclu-
sion does not contradict the non-cell-autonomous model of ALS
pathogenesis. In the chimeric transgenic model, astrocytes
appear to affect more on the progression of the disease process
rather than its initiation (Clement et al., 2003). Hence, our stem
cell model, which shows early events in disease onset, is consis-
tent with the notion that ALS pathogenesis initiates selectively in
MNs (Robberecht and Philips, 2013).
We have developed and incorporated multiple technologies to
establish enriched MN and non-MN cultures at a synchronized
maturation stage from both disease and isogenic controls, thus
overcoming major hurdles in disease modeling using PSCs.
Such a reproducible system enables us to reveal NF inclusion
as an early event in the cascade of MN neurite degeneration
in a cell-autonomous manner. Using advanced gene editing
technology, we have uncovered NF misregulation, especially
destabilization ofNF-LmRNA bymutant SOD1, as a critical early
step that leads to NF aggregation and axonal degeneration in
ALS MNs. This finding highlights the possibility of targeting NF
regulation for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Human PSCs
Fibroblasts from a 50-year-old female carrying the D90A SOD1 mutation
(ND29149, P3, Coriell Institute, http://www.coriell.org), were reprogrammed
using the nonintegrating Sendai virus as described (Ban et al., 2011). A4V
SOD1 mutant iPSC lines, established with retrovirus, were obtained from
Coriell (ND35671). The IMR-90-4 iPSC line, generated from fetal fibroblasts
(Hu et al., 2010), was used as a WT control. hESCs (WA09 line, NIH registry
0046) were used as an additional WT control and as a recipient for transgenic
expression of mutant SOD1 (Table S1).
Gene Editing of iPSCs and hESCs by TALEN-Mediated Homologous
Recombination
The donor plasmid for constitutive expression of D90A SOD1 was constructed
by replacing theCAG-GFP cassette of the plasmid AAV-CAGGS-EGFP (Addg-
ene, Cambridge, MA, http://www.addgene.org) with the CAG-D90A SOD1
cassette viaSpeI andMIuI double digestion (FigureS5). Similarly, theTet-induc-
ible expression plasmid was constructed by replacing the CAG-GFP cassette
with the CAG-Tet-On 3G cassette (pTRE3G-SV40-polyA cassette, Clontech,
Mountain View, CA, http://www.clontech.com) via the SpeI site (Figure S7).
NF-L cDNA sequence was inserted into the SalI and MIuI sites of the plasmid
for conditional NF-L expression (Figure S7). To correct the D90A mutation, a
986 bp or 829 bp fragment at both sides of the TALEN target point was PCR-
amplified using genomic DNA from hESCs (H9). The digested fragments were
then cloned into the multiple cloning site of plasmid PL452 (Frederick National
Lab). TALEN pairs targeting the SOD1 locus are illustrated in Figure S1E. With
Joung lab REAL assembly TALEN kit (Addgene), TALE repeat arrays targeting
AAVS1 or SOD1 locus were constructed using standard restriction digest and
ligation reactions. TALEN activity was assayed via surveyor nuclease (Transge-
nomic, Omaha, NE, http://www.transgenomic.com/). Standard protocol wasused for cellular transfection and cloning (Hockemeyer et al., 2011). The primer
sets were listed in Table S4.
MN and non-MN Differentiation
PSCs were first differentiated to neuroepithelia in a neural medium consisting
of DMEM/F12, N2 supplement, and nonessential amino acids in the presence
of SB431542 (2 mM), LDN193189 (300 nM), and CHIR99021 (3 mM, all from
Stemgent) for 7 days. At day 8, the neuroepithelia were treated with RA
(0.1 mM) and Purmorphamine (0.5mM) for 7 days for MN induction. For gener-
ation of non-MNs, cyclopamine (0.5 mM) was added in place of purmorph-
amine. At day 14, both MN and non-MN progenitors in the form of rosettes
were isolated and expanded as floating clusters in suspension in the same
respective medium but without SB431542, LDN193189, and CHIR99021 for
an additional 7 days before being plated on laminin substrate for the genera-
tion of mature neurons. To generate synchronized postmitotic neurons, the
cultures were treated from day 18 to 21 with compound E (0.1 mM) to block
cell proliferation.
Immunocytochemistry andQuantification of Aggregates andNeurite
Swelling
Immunofluorescent and immuno-EM staining on coverslip cultures was per-
formed as described (Li et al., 2008; Guillaume et al., 2006). Primary antibodies
are listed in Table S2. Cell counting was performed by a person blind to the
experiment using ImageJ (W. Rasband, NIMH, Bethesda, MD) and was repli-
cated in different cell lines. NF aggregates were defined as focal accumula-
tions of immunoreactive products with intensities of 3-fold higher than that
of their surroundings. Neurite swelling or beading was defined as an enlarge-
ment of a neurite that was at least twice the diameter of the neurite. At least 500
neurites were counted in each group. Statistical analyses were performed us-
ing one-way ANOVA (Tukey or Dunnett for multiple comparisons) in SPSS13.0.
Assays for mRNA Stability and RNA-Protein Interaction
Day 10MNs were treated with 10 mg/ml actinomycin D and RNAwas collected
every 2 hr for quantifying RNA levels of NF-L and b-actin.
RNA pulldown was performed according to the instruction of Pierce Mag-
netic RNA-Protein Pull-Down Kit (No.20164). Briefly, 300 bp 30 UTR of NF-L
fragment was cloned by PCR with a primer set as follows: Forward Primer
Sequence, 50GGTACCTAATACGACTCACTATAGGGGCTAAGAAGAAAGATT
GAAC (include T7 promoter) 30; Reverse Primer Sequence, 50GAGCTCGT
AAACATCTGAATGATTC30. RNA probe was in vitro synthesized by
AmpliScribe T7-Flash Transcription Kit (Epicenter) and purified with RNeasy
MinElute Cleanup Kit (QIAGEN). Five micrograms of RNA was labeled with
biotin by RNA 30 End Desthiobiotinylation kit. The labeled RNAwas conjugated
to streptavidin magnetic beads and incubated with protein lysate at 4C
overnight. After unbound proteins were washed from the beads, elute from
the beads was subject to western blotting analysis.
RT-PCR,Western Blotting, Genotyping, Allelic Imbalance Assay, and
ELISA and Electrophysiology
These are described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures, four tables,
and Supplemental Experimental Procedures and can be found with this article
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